FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4378782460> ?p ?o ?g. }

• W4378782460 abstract "Abstract Objective Local combined systemic therapy has been an important method for the treatment of unresectable hepatocellular carcinoma (HCC).The purpose of this study was to compare the effectiveness and safety of transarterial chemoembolization (TACE) plus Sorafenib versus TACE plus Apatinib for treating patients with unresectable HCC. Methods The clinical data of patients with unresectable HCC who were treated with TACE plus Sorafenib or TACE plus Apatinib at 5 Chinese medical centers between January 2016 and December 2020 were retrospectively analyzed. Propensity score matching (PSM) was applied to reduce the bias from confounding factors. Results A total of 380 patients were enrolled, of whom 129 cases were treated with TACE plus Sorafenib and 251 cases with TACE plus Apatinib. After the 1:1 PSM, 116 pairs of patients were involved in this study. The results showed that the PFS and OS in the TACE-Sorafenib group were significantly longer than those in the TACE-Apatinib group (PFS: 16.79 ± 6.45 vs. 14.76 ± 6.98 months, P = 0.049; OS: 20.66 ± 6.98 vs. 17.69 ± 6.72 months, P = 0.013). However, the ORR in the TACE-Apatinib group was markedly higher than that in the TACE-Sorafenib group (70.69% vs. 56.03%, P = 0.021). There were more patients with adverse events (AEs) in the TACE-Apatinib group than those in the TACE-Sorafenib group before dose adjustment (87 vs. 63, P = 0.001); however, the number of patients who suffered from AEs was not significantly different between the two groups after the dose adjustment (62 vs. 55, P = 0.148). No treatment-related death was found in the two groups. Subgroup analysis revealed that patients with unresectable HCC could better benefit from regular doses than reduced doses (Sorafenib, 22.59 vs. 18.02, P < 0.001; Apatinib, 19.75 vs. 16.86, P = 0.005). Conclusion TACE plus either Sorafenib or Apatinib could effectively treat patients with unresectable HCC, the safety of TACE plus Sorafenib was better. and the ORR of TACE plus Apatinib was higher." @default.
• W4378782460 created "2023-06-01" @default.
• W4378782460 creator A5007092930 @default.
• W4378782460 creator A5012463457 @default.
• W4378782460 creator A5032402468 @default.
• W4378782460 creator A5035327371 @default.
• W4378782460 creator A5049871921 @default.
• W4378782460 creator A5057968753 @default.
• W4378782460 creator A5062277826 @default.
• W4378782460 creator A5078222678 @default.
• W4378782460 creator A5080207575 @default.
• W4378782460 date "2023-05-30" @default.
• W4378782460 modified "2023-10-14" @default.
• W4378782460 title "Comparing the effectiveness and safety of Sorafenib plus TACE with Apatinib plus TACE for treating patients with unresectable hepatocellular carcinoma: a multicentre propensity score matching study" @default.
• W4378782460 cites W1507812686 @default.
• W4378782460 cites W1971837077 @default.
• W4378782460 cites W1975113490 @default.
• W4378782460 cites W1994193851 @default.
• W4378782460 cites W2039800254 @default.
• W4378782460 cites W2061345986 @default.
• W4378782460 cites W2113935263 @default.
• W4378782460 cites W2137052325 @default.
• W4378782460 cites W2140016882 @default.
• W4378782460 cites W2140765540 @default.
• W4378782460 cites W2230771669 @default.
• W4378782460 cites W2268557403 @default.
• W4378782460 cites W2276228008 @default.
• W4378782460 cites W2283064216 @default.
• W4378782460 cites W2293170306 @default.
• W4378782460 cites W2296028965 @default.
• W4378782460 cites W2346435459 @default.
• W4378782460 cites W2407351686 @default.
• W4378782460 cites W2605741526 @default.
• W4378782460 cites W2617206715 @default.
• W4378782460 cites W2625261780 @default.
• W4378782460 cites W2762066258 @default.
• W4378782460 cites W2768054876 @default.
• W4378782460 cites W2789990585 @default.
• W4378782460 cites W2803786348 @default.
• W4378782460 cites W2808335738 @default.
• W4378782460 cites W2887865671 @default.
• W4378782460 cites W2900312813 @default.
• W4378782460 cites W2902296557 @default.
• W4378782460 cites W3025493604 @default.
• W4378782460 cites W3033994809 @default.
• W4378782460 cites W3082042226 @default.
• W4378782460 cites W3094135792 @default.
• W4378782460 doi "https://doi.org/10.1186/s40644-023-00574-7" @default.
• W4378782460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37254146" @default.
• W4378782460 hasPublicationYear "2023" @default.
• W4378782460 type Work @default.
• W4378782460 citedByCount "1" @default.
• W4378782460 countsByYear W43787824602023 @default.
• W4378782460 crossrefType "journal-article" @default.
• W4378782460 hasAuthorship W4378782460A5007092930 @default.
• W4378782460 hasAuthorship W4378782460A5012463457 @default.
• W4378782460 hasAuthorship W4378782460A5032402468 @default.
• W4378782460 hasAuthorship W4378782460A5035327371 @default.
• W4378782460 hasAuthorship W4378782460A5049871921 @default.
• W4378782460 hasAuthorship W4378782460A5057968753 @default.
• W4378782460 hasAuthorship W4378782460A5062277826 @default.
• W4378782460 hasAuthorship W4378782460A5078222678 @default.
• W4378782460 hasAuthorship W4378782460A5080207575 @default.
• W4378782460 hasBestOaLocation W43787824601 @default.
• W4378782460 hasConcept C126322002 @default.
• W4378782460 hasConcept C143998085 @default.
• W4378782460 hasConcept C17923572 @default.
• W4378782460 hasConcept C197934379 @default.
• W4378782460 hasConcept C2776694085 @default.
• W4378782460 hasConcept C2778019345 @default.
• W4378782460 hasConcept C2778455285 @default.
• W4378782460 hasConcept C2778695046 @default.
• W4378782460 hasConcept C2778822529 @default.
• W4378782460 hasConcept C2779984678 @default.
• W4378782460 hasConcept C2780668389 @default.
• W4378782460 hasConcept C3019894029 @default.
• W4378782460 hasConcept C71924100 @default.
• W4378782460 hasConcept C90924648 @default.
• W4378782460 hasConceptScore W4378782460C126322002 @default.
• W4378782460 hasConceptScore W4378782460C143998085 @default.
• W4378782460 hasConceptScore W4378782460C17923572 @default.
• W4378782460 hasConceptScore W4378782460C197934379 @default.
• W4378782460 hasConceptScore W4378782460C2776694085 @default.
• W4378782460 hasConceptScore W4378782460C2778019345 @default.
• W4378782460 hasConceptScore W4378782460C2778455285 @default.
• W4378782460 hasConceptScore W4378782460C2778695046 @default.
• W4378782460 hasConceptScore W4378782460C2778822529 @default.
• W4378782460 hasConceptScore W4378782460C2779984678 @default.
• W4378782460 hasConceptScore W4378782460C2780668389 @default.
• W4378782460 hasConceptScore W4378782460C3019894029 @default.
• W4378782460 hasConceptScore W4378782460C71924100 @default.
• W4378782460 hasConceptScore W4378782460C90924648 @default.
• W4378782460 hasIssue "1" @default.
• W4378782460 hasLocation W43787824601 @default.
• W4378782460 hasLocation W43787824602 @default.
• W4378782460 hasOpenAccess W4378782460 @default.
• W4378782460 hasPrimaryLocation W43787824601 @default.
• W4378782460 hasRelatedWork W2368404834 @default.
• W4378782460 hasRelatedWork W2370121646 @default.
• W4378782460 hasRelatedWork W2549993205 @default.

• next